{"id":"envafolimab-plus-gemcitabine-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4298006","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Envafolimab specifically targets the PD-1 receptor on T-cells, preventing the binding of PD-L1 and PD-L2, which are often overexpressed on tumor cells. This inhibition leads to enhanced T-cell activation and proliferation, promoting an immune response against cancer cells.","oneSentence":"Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:51:03.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT04910386","phase":"PHASE2","title":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2027-06-01","conditions":"Biliary Tract Neoplasms","enrollment":126},{"nctId":"NCT06059261","phase":"PHASE2","title":"Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2026-02-09","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT07003815","phase":"PHASE2","title":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06","conditions":"Biliary Tract Cancer, Advanced Cancer","enrollment":62},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06013943","phase":"PHASE2","title":"Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2023-03-17","conditions":"Gallbladder Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Envafolimab plus Gemcitabine&Cisplatin","genericName":"Envafolimab plus Gemcitabine&Cisplatin","companyName":"3D Medicines (Sichuan) Co., Ltd.","companyId":"3d-medicines-sichuan-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}